A study finds that a mass drug administration (MDA) in Monrovia, Liberia, during the Ebola outbreak appears to have reduced the incidence of malaria throughout the city.
Researchers report the minimum serum concentrations required to protect mice against 10 times a 50% lethal dose of ricin.
Doctors in Sierra Leone treated approximately 100 Ebola patients with a combination of atorvastatin and irbesartan.
The US Biomedical Advanced Research and Development Authority (BARDA) and Regeneron Pharmaceuticals have partnered to develop a pair of antibodies to prevent and treat Middle East Respiratory Syndrome (MERS).
Phase I Clinical Trials are underway for SAB Biotherapeutics’ antibody treatment (SAB-301) for Middle East Respiratory Syndrome.
This document discusses the efficacy of ciprofloxacin therapy for pneumonic plague, nonclinical pharmacokinetics of ciprofloxacin and translation to human dosing, ciprofloxacin safety, and the benefit/risk of ciprofloxacin treatment of pneumonic plague.
This report addresses elements of hospital-based acute care, specifically antitoxins and intravenous antimicrobial use, and the diagnosis and management of common anthrax-specific complications during a mass-casualty incident.
Medicines for Malaria Venture distributed 400 compounds with antimalarial activity free to 200 labs in 30 countries.